These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9217577)

  • 1. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients.
    Laguna-del-Estal P; Moya-Mir MS
    Am J Med; 1997 Feb; 102(2):222. PubMed ID: 9217577
    [No Abstract]   [Full Text] [Related]  

  • 2. Secondary prophylaxis for visceral leishmaniasis in HIV-infected individuals.
    Pérez-Molina JA; López-Vélez ; Guerrero A
    Am J Med; 1997 Jan; 102(1):132. PubMed ID: 9209216
    [No Abstract]   [Full Text] [Related]  

  • 3. Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients.
    Pérez-Molina JA; López-Vélez R; Montilla P; Guerrero A
    AIDS; 1996 Feb; 10(2):237-8. PubMed ID: 8838721
    [No Abstract]   [Full Text] [Related]  

  • 4. Liposomal Amphotericin B drug access for the treatment of leishmaniasis in Brazil.
    Mistro S; Rodrigues M; Rosa L; Camargo M; Badaró R
    Trop Med Int Health; 2016 Jun; 21(6):692-3. PubMed ID: 27037644
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study.
    Diro E; Ritmeijer K; Boelaert M; Alves F; Mohammed R; Abongomera C; Ravinetto R; De Crop M; Fikre H; Adera C; Colebunders R; van Loen H; Menten J; Lynen L; Hailu A; van Griensven J
    PLoS Negl Trop Dis; 2015; 9(10):e0004087. PubMed ID: 26431253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal amphotericin B as first line and secondary prophylactic treatment for visceral leishmaniasis in a patient infected with HIV.
    Borrelli P; Imperato A; Murdaca G; Scudeletti M
    Ann Ital Med Int; 2000; 15(2):169-71. PubMed ID: 10920508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical leishmaniasis in a patient infected with human immunodeficiency virus.
    Mondain-Miton V; Toussaint-Gari M; Hofman P; Marty P; Carles M; De Salvador F; Miton F; Le Fichoux Y; Dellamonica P
    Clin Infect Dis; 1995 Sep; 21(3):663-5. PubMed ID: 8527563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV.
    López-Vélez R
    Ann Trop Med Parasitol; 2003 Oct; 97 Suppl 1():143-7. PubMed ID: 14678641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of visceral leishmaniasis: recent modalities].
    Gangneux JP
    Presse Med; 1999 Nov; 28(37):2057-66. PubMed ID: 10605480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical survey of Leishmania/HIV co-infection in Catania, Italy: the impact of highly active antiretroviral therapy (HAART).
    Russo R; Nigro L; Panarello G; Montineri A
    Ann Trop Med Parasitol; 2003 Oct; 97 Suppl 1():149-55. PubMed ID: 14678642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous leishmaniasis associated with visceral leishmaniasis in a case of acquired immunodeficiency syndrome (AIDS).
    Pourahmad M; Hooshmand F; Rahiminejad M
    Int J Dermatol; 2009 Jan; 48(1):59-61. PubMed ID: 19126052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
    Torre-Cisneros J; Villanueva JL; Kindelan JM; Jurado R; Sanchez-Guijo P
    Clin Infect Dis; 1993 Oct; 17(4):625-7. PubMed ID: 8268341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Itraconazole as maintenance therapy for visceral leishmaniasis in HIV-infected patients.
    Angarano G; Maggi P; Coppola SL; Cavaliere RL
    Eur J Clin Microbiol Infect Dis; 1998 May; 17(5):365-7. PubMed ID: 9721971
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of liposomal amphotericin B in the treatment and secondary prophylaxis of visceral leishmaniasis in HIV infected patients: report of two cases.
    Lopez Dupla M; Gil Aguado A; Lavilla Uriol P; Pintado Garcia V; Valencia Ortega E; Martinez Martinez P; Garcia-Puig J
    J Antimicrob Chemother; 1993 Oct; 32(4):657-9. PubMed ID: 8288512
    [No Abstract]   [Full Text] [Related]  

  • 15. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.
    ter Horst R; Collin SM; Ritmeijer K; Bogale A; Davidson RN
    Clin Infect Dis; 2008 Jun; 46(11):1702-9. PubMed ID: 18419422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronidazole treatment in a patient with AIDS and visceral leishmaniasis.
    Arranz-Caso JA; Albarrán-Hernández F; Cuadrado-Gómez LM; Gonzalez-Palacios R
    AIDS; 1995 Dec; 9(12):1377-8. PubMed ID: 8605059
    [No Abstract]   [Full Text] [Related]  

  • 17. Engima of therapeutic failure in visceral leishmaniasis.
    Arya SC
    J Assoc Physicians India; 1993 Mar; 41(3):155-8. PubMed ID: 8226600
    [No Abstract]   [Full Text] [Related]  

  • 18. Secondary prophylaxis for Leishmania infection in an HIV-positive patient.
    Orlando G; Del Sorbo F; Corbellino M; Schiavini M; Cargnel A
    AIDS; 1998 Oct; 12(15):2086-7. PubMed ID: 9814886
    [No Abstract]   [Full Text] [Related]  

  • 19. AIDS and leishmaniasis.
    Davidson RN
    Genitourin Med; 1997 Aug; 73(4):237-9. PubMed ID: 9389941
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and tolerance of amphotericin B in a lipid emulsion in the treatment of visceral leishmaniasis in AIDS patients.
    Petit N; Parola P; Dhiver C; Gastaut JA
    J Antimicrob Chemother; 1996 Jul; 38(1):154-7. PubMed ID: 8858471
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.